innat
viral
inhibitor
broadli
activ
character
serum
nervou
system
incomplet
character
gastrointestin
gi
tract
gi
prepar
porcin
gastric
mucosa
mous
intestin
neuramid
pharmaceut
product
examin
broad
antivir
activ
molecular
size
mechan
action
comparison
previous
character
innat
inhibitor
serum
nervou
system
gi
inhibitor
found
activ
high
titer
rna
dna
virus
resist
proteolysi
glycolysi
lipid
extract
possess
differ
mechan
action
mous
intestin
inhibitor
prevent
viru
attach
cell
neuramid
act
earli
postattach
stage
viru
multipl
porcin
mucos
inhibitor
act
late
h
initi
multipl
cycl
broadli
activ
gi
inhibitor
differ
previous
describ
serum
inhibitor
utib
high
densiti
lipoprotein
hdl
nervou
system
ns
inhibitor
smaller
kda
resist
proteinas
k
glycosidas
organ
solvent
mous
intestin
inhibitor
act
similarli
utib
ns
inhibitor
prevent
attach
viru
cell
comparison
neuramid
porcin
mucos
inhibitor
like
hdl
act
attach
target
cell
innat
nonspecif
broadlyact
viru
inhibitor
base
high
titer
locat
consid
import
initi
immun
defens
mechan
viral
infect
thu
potenti
use
medic
applic
mani
nonspecif
viral
inhibitor
bodi
fluid
tissu
describ
activ
virus
karzon
low
baron
holland
baron
et
al
krizanova
rathova
kitamura
et
al
thiri
et
al
gerna
et
al
particular
interest
broadli
activ
viral
inhibitor
kumar
et
al
baron
et
al
baron
et
al
baron
et
al
singh
et
al
singh
et
al
singh
et
al
could
import
afford
natur
protect
mani
viral
infect
baron
et
al
medic
use
purpos
studi
determin
properti
broadli
activ
inhibitor
associ
gastrointestin
gi
tract
includ
size
structur
activ
chemic
moieti
mechan
action
broadli
activ
viral
inhibitor
report
certain
bodi
tissu
fluid
singh
et
al
singh
et
al
singh
et
al
inhibitor
includ
highdens
lipoprotein
plasma
singh
et
al
utib
plasma
singh
et
al
ns
inhibitor
distribut
throughout
central
peripher
nervou
system
singh
et
al
inhibitor
distinct
present
gi
inhibitor
determin
properti
mechan
antivir
action
find
gi
inhibitor
compar
properti
innat
inhibitor
report
previous
variou
bodi
tissu
fluid
porcin
mucos
neuramid
mous
intestin
inhibitor
use
porcin
mucos
prepar
nation
formulari
xii
specif
obtain
american
laboratori
omaha
ne
porcin
prepar
dissolv
eagl
minimum
essenti
medium
emem
ratio
ml
per
g
origin
net
weight
antivir
activ
express
unitsml
solut
neuramid
partial
purifi
proprietari
extract
gastric
mucosa
milk
use
medic
treat
viral
infect
human
start
materi
clarifi
heat
extract
lipid
solvent
obtain
difacoop
milan
itali
clear
tancolor
solut
process
use
mous
intestin
inhibitor
prepar
made
intestin
isol
g
icr
femal
mice
harlan
spragu
dawley
houston
tx
intestin
wash
hank
balanc
salt
solut
hbss
one
set
sampl
mlg
intestin
prepar
flush
medium
lumen
set
minc
wash
three
time
suspend
medium
two
time
volum
weight
h
prepar
vortex
thoroughli
centrifug
revmin
min
supernat
centrifug
revmin
min
filter
corn
filter
filtrat
aliquot
amount
store
use
two
prepar
equal
antivir
activ
eluat
minc
wash
prepar
use
character
thu
initi
character
studi
centrifug
filter
inhibitor
prepar
use
initi
establish
major
properti
experi
perform
least
two
time
often
four
time
antivir
titer
inhibitor
determin
viru
plaqu
reduct
assay
previous
describ
baron
mckerli
virus
use
poxviru
vaccinia
ihd
strain
herp
viru
herp
simplex
heitzman
strain
enterovirus
poliomyel
type
mahoney
strain
mengoviru
mv
alphaviru
sindbi
egar
strain
sbv
bunyaviru
bunyamwera
origin
strain
rhabdoviru
vesicular
stomat
indiana
strain
vsv
virus
origin
obtain
nation
institut
health
bethesda
md
sinc
maintain
laboratori
kumar
et
al
baron
et
al
singh
et
al
vero
cell
african
green
monkey
kidney
cell
american
type
cultur
collect
ccl
use
assay
inhibitor
antivir
activ
express
unit
per
ml
one
unit
u
determin
reciproc
highest
dilut
inhibitor
prepar
show
inhibit
plaqueform
unit
pfu
use
challeng
assay
includ
least
two
replic
result
confirm
repeat
experi
neuramid
use
posit
viru
inhibitor
control
assay
molecular
size
neuramid
mous
intestin
inhibitor
perform
softgel
high
perform
liquid
chromatographi
hplc
support
preliminari
determin
perform
calibr
cm
biogel
biorad
column
equilibr
mm
tri
hcl
ph
uv
absorb
monitor
nm
fraction
collect
fraction
assay
antivir
activ
result
confirm
hplc
two
synchropak
gpc
peptid
column
mm
synchrom
lafayett
connect
seri
filter
centrifug
sampl
ml
appli
column
run
sodium
phosphat
buffer
ph
fraction
ml
collect
assay
antivir
activ
chemic
composit
inhibitor
investig
lipid
extract
enzymat
degrad
determin
effect
lipid
extract
inhibitor
sampl
extract
five
time
equal
amount
nbutanol
two
time
ethyl
ether
singh
et
al
organ
aqueou
phase
separ
residu
organ
solvent
remov
aqueou
phase
evapor
speedvac
ae
savant
instrument
inc
farmingdal
ny
assay
antivir
activ
effect
proteolysi
determin
use
immobil
proteinas
k
sigma
st
loui
mo
singh
et
al
briefli
ml
inhibitor
sampl
preadjust
ph
incub
mg
proteinas
k
hydrat
h
rotari
shaker
enzym
bead
remov
centrifug
supernat
assay
antivir
activ
role
complex
carbohydr
essenti
structur
antivir
activ
determin
period
oxid
enzymat
deglycosyl
singh
et
al
briefli
period
oxid
achiev
ad
naio
inhibitor
sampl
ph
incub
h
sampl
dialyz
molecular
weight
cut
mwco
membran
remov
naio
assay
antivir
mwco
membran
activ
control
experi
show
io
although
slightli
larger
dalton
pass
membran
entir
presum
due
toler
rang
includ
io
deglycosyl
perform
modifi
techniqu
bose
et
al
singh
et
al
treat
inhibitor
mixtur
carbohydras
consist
agalactosidas
boehring
mannheim
indianapoli
bnacetylglucosaminidas
sigma
st
loui
mo
endoglycosidas
sigma
neuraminidas
sigma
bmannosidas
sigma
inhibitor
sampl
preadjust
ph
mix
ml
glycosidas
mixtur
incub
rotari
shaker
h
ad
sulfhydryl
reduc
agent
dithiothreitol
dtt
final
concentr
mixtur
incub
h
modifi
procedur
omit
dtt
mous
intestin
inhibitor
sinc
point
found
small
size
inhibitor
unfold
small
molecul
requir
penetr
glycosidas
sampl
contain
ddt
dialyz
remov
dtt
assay
residu
antivir
activ
singh
et
al
singh
et
al
mechan
action
inhibitor
studi
investig
whether
antivir
activ
due
directli
revers
neutral
virion
inhibit
viru
attach
cell
inhibit
viru
replic
postattach
cell
induct
antivir
activ
target
cell
describ
test
abil
inhibitor
irrevers
neutral
viru
determin
previous
describ
kumar
et
al
use
plaqu
reduct
assay
virus
twentyfour
uml
inhibitor
pfu
viru
mix
incub
h
mixtur
dilut
beyond
inhibitori
titer
inhibitor
assay
recoveri
residu
infecti
viru
effect
inhibitor
attach
sindbi
sbv
vesicular
stomat
vsv
mengovirus
mv
examin
compar
inhibitori
titer
h
viru
attach
penetr
occur
temperatur
viru
attach
penetr
kumar
et
al
singh
et
al
effect
viru
challeng
pfu
moi
allow
infect
confluent
vero
cell
microtit
plate
cultur
wash
three
time
overlaid
ml
methylcellulos
hepe
buffer
cultur
medium
mc
plaqu
stain
crystal
violet
read
day
time
viru
growth
cycl
viru
replic
inhibit
determin
describ
previous
singh
et
al
inhibitor
uml
ad
variou
time
time
onestep
growth
cycl
viru
viru
yield
determin
end
singl
cycl
growth
harvest
viru
h
synchron
initi
viru
replic
design
h
obtain
infect
cell
monolay
pfu
moi
viru
cell
cultur
plate
h
allow
viru
attach
cell
wash
three
time
cold
emem
remov
unabsorb
viru
inhibitor
refe
warm
inhibitor
emem
contain
fb
incub
total
h
singl
cycl
viru
replic
cultur
store
viru
yield
quadrupl
well
pool
viru
plaqu
assay
viru
yield
determin
titrat
pfu
vero
cell
viru
dilut
use
inact
viru
low
concentr
time
product
interferon
would
late
influenc
singl
growth
cycl
possibl
induct
antivir
state
cell
eg
like
interferon
ifn
inhibitor
determin
describ
previous
singh
et
al
confluent
monolay
vero
cell
incub
overnight
serial
dilut
inhibitor
prepar
allow
antivir
activ
develop
cell
wash
three
time
emem
remov
noncel
associ
inhibitori
activ
challeng
pfu
viru
h
incub
cell
overlaid
mc
plaqu
reduct
end
point
calcul
three
sampl
type
test
varieti
size
exclus
column
antivir
activ
consist
emerg
column
volum
support
indic
activ
moieti
small
size
calibr
column
activ
began
separ
salt
peak
gave
inconclus
result
synchropak
gpc
peptid
hplc
column
abl
resolv
small
peptid
neuramid
porcin
mucos
mous
intestin
inhibitor
emerg
appar
molecular
size
b
da
consist
result
dialysi
experi
antivir
activ
unretain
smallest
da
mwco
membran
base
gpc
peptid
result
assign
tent
molecular
weight
da
antivir
moieti
prepar
determin
breadth
antivir
activ
three
gastrointestin
extract
assay
antivir
activ
five
virus
antivir
activ
three
gastrointestin
inhibitor
broad
virus
test
includ
dna
viru
envelop
nonenvelop
rna
virus
inhibit
tabl
titer
inhibitor
substanti
rang
uml
statist
signific
differ
antivir
activ
inhibitor
compar
small
molecular
weight
dialys
mw
membran
broad
activ
retent
inact
control
prepar
kidney
liver
tissu
gave
titer
b
uml
medium
control
neg
thu
three
gastrointestin
extract
contain
signific
titer
broadli
antivir
substanc
determin
structur
composit
requir
antivir
activ
extract
treat
degrad
protein
break
carbohydr
linkag
oxid
carbohydr
extract
lipid
residu
antivir
activ
measur
treatment
neuramid
porcin
mucos
mous
intestin
prepar
either
proteinas
k
carbohydras
sodium
period
extract
lipid
solvent
butanol
ethyl
ether
affect
antivir
activ
tabl
sinc
carbohydras
would
degrad
possibl
sugar
linkag
expect
present
gi
tract
also
treat
naio
gener
oxid
agent
neg
result
previous
treatment
appropri
inactiv
antivir
inhibitor
bodi
tissu
fluid
laboratori
singh
et
al
singh
et
al
find
intestin
prepar
suggest
protein
carbohydr
lipid
moieti
may
requir
antivir
activ
gi
inhibitor
determin
whether
intestin
prepar
directli
inactiv
virus
virus
pretreat
uml
inhibitor
assay
residu
infect
titer
pretreat
sbv
vsv
mv
neuramid
porcin
mucos
extract
mous
intestin
inhibitor
chang
infect
titer
significantli
data
shown
indic
bind
irrevers
virion
perman
neutral
infect
would
neutral
antibodi
determin
whether
inhibitor
act
attach
later
replic
cycl
inhibitori
titer
inhibitor
compar
rational
temperatur
experi
cell
membran
physiolog
inert
henc
viru
replic
proceed
beyond
initi
attach
target
cell
compar
titer
therefor
impli
antivir
substanc
inhibit
attach
viru
target
cell
significantli
higher
titer
impli
inhibitor
act
postattach
stage
tabl
show
titer
neuramid
porcin
mucos
inhibitor
sbv
vsv
mv
significantli
lower
assay
indic
neuramid
porcin
mucos
inhibitor
may
act
block
viral
replic
postattach
stage
mous
intestin
inhibitor
hand
activ
therefor
inhibit
viru
replic
prevent
attach
virion
target
cell
determin
inhibitor
act
viru
growth
cycl
carri
timedaddit
inhibitor
singlecycl
yieldreduct
experi
specif
determin
viru
yield
addit
inhibitor
prepar
infect
cell
monolay
variou
time
c
clarifi
filter
prepar
without
purif
use
describ
section
neuramid
adjust
ph
isoton
dialysi
balanc
salt
solut
neuramid
would
suspend
medium
prepar
synchron
infect
viru
titer
measur
singl
growth
cycl
h
avoid
possibl
complic
stem
suppress
subsequ
growth
cycl
residu
inhibitor
shown
fig
inhibitor
prepar
ad
h
left
cultur
reduc
yield
sbv
inhibitor
ad
h
later
porcin
mucos
inhibitor
reduc
yield
sbv
thu
porcin
mucos
inhibitor
caus
inhibit
viru
replic
attach
viru
cell
long
h
initi
growth
cycl
comparison
presenc
mous
intestin
inhibitor
neuramid
inhibit
occur
h
indic
inhibit
either
attach
intestin
inhibitor
earli
postattach
neuramid
thu
observ
consist
experi
discuss
later
determin
cell
acquir
resist
viru
infect
pretreat
inhibitor
incub
inhibitor
prepar
mous
intestin
neuramid
porcin
mucosa
h
wash
viru
challeng
pretreat
cell
exhibit
resist
subsequ
infect
sbv
vsv
mv
data
shown
indic
unlik
interferon
inhibitor
induc
durabl
antivir
state
target
cell
gener
viral
infect
specif
immun
preced
innat
nonspecif
defens
baron
et
al
baron
et
al
specif
immun
gener
begin
day
post
viral
infect
viru
multipl
start
decreas
earlier
day
post
infect
baron
et
al
baron
et
al
earli
decreas
viru
attribut
interferon
inflamm
innat
viral
inhibitor
baron
et
al
antivir
activ
innat
inhibitor
individu
famili
virus
report
resid
varieti
uncharacter
partli
character
substanc
distinguish
antibodi
interferon
complement
mani
antivir
substanc
gener
report
act
singl
virus
coronavirus
newcastl
diseas
viru
variola
viru
sendai
viru
vesicular
stomat
viru
karzon
kitamura
et
al
thiri
et
al
sinibaldi
et
al
gerna
et
al
activ
individu
viru
famili
includ
myxovirus
togavirus
retrovirus
krizanova
rathova
shortridg
ho
welsh
et
al
mechan
action
viral
inhibitor
known
vari
act
irrevers
neutral
infect
case
coronaviru
sendai
viru
inhibitor
karzon
kitamura
et
al
sinibaldi
et
al
gerna
et
al
myxoand
togaviru
inhibitor
appear
prevent
hemaglutin
infect
krizanova
rathova
shortridg
ho
inhibitor
vesicular
stomat
viru
act
penetr
viral
envelop
inactiv
viral
rna
thiri
et
al
retroviru
inhibitor
work
via
complementmedi
lysi
viral
infect
cell
welsh
et
al
among
innat
nonspecif
viral
inhibitor
present
variou
tissu
broadli
activ
inhibitor
specif
interest
present
studi
may
function
prevent
infect
mani
virus
singh
et
al
baron
et
al
broadli
activ
nonspecif
viral
inhibitor
present
plasma
nervou
system
human
rabbit
mice
baron
et
al
character
singh
et
al
singh
et
al
singh
et
al
vivo
protect
role
nervou
tissu
inhibitor
viral
infect
shown
baron
et
al
gi
tract
inhibitor
also
found
mice
rabbit
human
fulli
character
baron
et
al
present
studi
done
character
essenti
structur
gi
inhibitor
murin
porcin
origin
studi
show
mous
intestin
porcin
mucos
inhibitor
neuramid
prepar
activ
number
dna
rna
virus
antivir
activ
rang
ug
ml
tabl
molecular
size
da
appear
resist
lipid
solvent
proteolysi
glycolysi
resist
degrad
gi
inhibitor
could
signific
vivo
sinc
remain
activ
gi
tract
inhibitor
must
resist
action
variou
lipolyt
proteolyt
glycolyt
activ
digest
process
interest
possibl
antivir
defens
molecul
evolv
resist
digest
enzym
exampl
protein
gueant
et
al
festen
carbohydr
engfer
et
al
vonk
et
al
highli
resist
digest
enzym
report
exampl
includ
iga
vitamin
absorpt
factor
studi
antivir
mechan
allow
limit
infer
made
even
though
gi
inhibitor
impur
inhibitor
neither
directli
inactiv
infecti
virion
induc
antivir
state
cell
thu
inhibit
requir
continu
presenc
inhibitor
viru
cell
possibl
inhibitori
mechan
includ
low
affin
bind
inhibitor
viru
cell
competit
inhibit
rapid
revers
antivir
effect
possibl
studi
gi
inhibitor
appear
act
differ
stage
multipl
cycl
sbv
shown
experi
inhibitori
activ
addit
inhibitor
differ
time
interv
singlecycl
viru
multipl
mous
intestin
prepar
appear
prevent
viru
attach
activ
temperatur
viru
attach
may
occur
tabl
consist
inhibi
tion
viru
attach
mous
intestin
inhibitor
earli
inhibitori
action
ad
h
singl
cycl
viru
multipl
fig
comparison
neuramid
activ
tabl
indic
act
postattach
stage
viru
multipl
postattach
inhibit
must
earli
howev
neuramid
lose
inhibitori
activ
ad
h
postinfect
fig
antivir
action
porcin
mucos
inhibitor
appear
occur
late
viru
multipl
cycl
act
tabl
indic
viru
attach
inhibit
ad
late
h
viru
infect
strongli
inhibit
viru
multipl
indic
act
late
viru
growth
cycl
possibl
mechan
action
must
eventu
confirm
use
purifi
inhibitor
molecular
probe
consist
defens
role
gi
tract
inhibitor
natur
high
titer
broad
antivir
activ
includ
enteroviru
locat
gi
tract
lumen
interestingli
elut
secret
distinct
viral
inhibitor
extracellular
fluid
report
nervou
tissu
baron
et
al
found
use
kidney
liver
definit
assign
defens
role
futur
studi
show
administr
inhibitor
protect
vivo
delet
inhibitor
enhanc
infect
gi
inhibitor
host
defens
mechan
may
specul
may
eventu
medic
applic
possibl
medic
applic
may
made
like
small
size
inhibitor
may
make
synthesi
practic
also
result
less
antigen
present
character
gi
inhibitor
allow
comparison
properti
broadlyact
antivir
innat
substanc
report
bodi
fluid
tissu
baron
et
al
baron
et
al
baron
et
al
kumar
et
al
singh
et
al
singh
et
al
singh
et
al
tabl
shown
first
column
tabl
broadli
activ
antivir
substanc
present
plasma
nervou
system
gi
tract
howev
differ
size
chemi
cal
structur
mechan
action
shown
third
column
gi
inhibitor
rel
small
kda
compar
larg
molecular
complex
plasma
kda
nervou
system
kda
interestingli
kda
molecular
weight
inhibitor
plasma
utib
kda
inhibitor
nervou
system
ns
broken
activ
smaller
size
inhibitor
kda
similar
size
gi
inhibitor
baron
et
al
singh
et
al
singh
et
al
addit
small
peptid
apolipoprotein
hdl
retain
antivir
activ
sriniva
et
al
thu
smaller
molecular
compon
larger
inhibitor
appear
inhibitori
viral
inhibitori
assay
indic
except
hdl
occur
high
titer
start
least
uml
g
column
high
titer
rang
interferon
establish
host
defens
gi
inhibitor
lowest
molecular
weight
da
column
resist
lipid
extract
proteolyt
glycolyt
enzymat
digest
column
hand
ns
inhibitor
larg
molecul
kda
inactiv
proteinas
glycosidas
hdl
molecular
size
kda
peptid
structur
appear
respons
antivir
activ
utib
glycoprotein
kda
carbohydr
antivir
moieti
mechan
action
column
mous
intestin
inhibitor
utib
ns
inhibitor
occur
viru
stage
attach
hdl
inhibit
stage
viru
penetr
neuramid
act
earli
postattach
phase
porcin
gastric
mucos
prepar
act
late
postattach
phase
conclus
innat
broadspectrum
antivir
molecul
occur
wide
bodi
tissu
fluid
signific
titer
consid
import
initi
barrier
viral
infect
therebi
also
offer
potenti
medic
use
futur
studi
need
purif
studi
molecular
structur
biosynthesi
mechan
action
medic
applic
